MedPath

Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma

Phase 3
Terminated
Conditions
Stage II/III
T3 or T4 (Only Anal Extension) Rectal Cancer
N0-2
M0
Rectal Cancer
Interventions
Registration Number
NCT00207831
Lead Sponsor
Institut Cancerologie de l'Ouest
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as 5-fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing and also as a radiosensibilisant. Radiation therapy uses high-energy x-rays to kill tumor cells. 5-fluorouracil may make tumor cells more sensitive to radiation therapy. Oral 5-fluorouracil is more convenient for ambulatory patients. Giving UFT (Tegafur and Uracil) with radiation therapy before surgery may shrink the tumor so it can be removed.

PURPOSE: This phase III trial is studying how well giving UFT with radiation therapy works in treating patients who are undergoing surgery for operable rectal cancer.

Detailed Description

Adenocarcinoma of the rectum

Stage II/stage III rectal cancer (if T4 only anal extension eligible)

Drug: UFT

Procedure: chemotherapy

Procedure: conventional surgery

Procedure: neoadjuvant therapy

Procedure: radiation therapy

Procedure: radiosensitization

Procedure: surgery

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
219
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tegafur uracile + radiotherapyTegafur and Uracil-
radiotherapyTegafur and Uracil-
Primary Outcome Measures
NameTimeMethod
Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone
Secondary Outcome Measures
NameTimeMethod
Compare endoscopic ultrasonographic response in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone.
Compare quality of life (Quality of Life Questionnaire Core 30 Items [QLQ-C 30])
Compare the safety of the chemoradiotherapy regimen to radiotherapy alone
Compare overall survival
Compare the rate of sphincter conservation alone.
Compare the rate of resectability with negative resection margins in patients treated with this two regimen.
Compare recurrence free survival and disease free survival

Trial Locations

Locations (24)

Centre Guillaume le Conquérant

🇫🇷

Le Havre, France

Centre Oscar Lambret

🇫🇷

Lille, France

Clinique du Pont de Chaume

🇫🇷

Montauban, France

Centre Hospitalier de Cornouaille

🇫🇷

Quimper, France

Clinique Fleming

🇫🇷

Tours, France

Centre des Hautes Energies

🇫🇷

Toulouse, France

Centre de Radiothérapie

🇫🇷

Strasbourg, France

Institut de Cancérologie et d'Hématologie

🇫🇷

Brest, France

Hopital Avicenne

🇫🇷

Bobigny, France

Clinique Sainte Catherine

🇫🇷

Avignon, France

Centre Hospitalier

🇫🇷

Rodez, France

Centre d'Oncologie-radiothérapie d'Eure et Loir

🇫🇷

Chartres, France

Centre Hospitalier Départemental

🇫🇷

La Roche Sur Yon, France

Clinique du Mail

🇫🇷

Grenoble, France

Centre Jean Perrin

🇫🇷

Clermont Ferrand, France

Centre Médical République

🇫🇷

Clermont-ferrand, France

Centre léon Bérard

🇫🇷

LYON Cedex 08, France

Centre Gray

🇫🇷

Maubeuge, France

Polyclinique St Roch

🇫🇷

Montpellier, France

Clinique Valdegour

🇫🇷

Nimes, France

Centre Hospitalier Universitaire

🇫🇷

Poitiers, France

Centre Eugène Marquis

🇫🇷

Rennes, France

Centre Frédéric Joliot

🇫🇷

Rouen, France

Clinique Armoricaine de Radiologie

🇫🇷

Saint Brieuc, France

© Copyright 2025. All Rights Reserved by MedPath